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Purpose. To evaluate the correlation between MRI and histopathological ﬁndings in patients with mammographically detected
3–5 BI-RAD (Breast Imaging Reporting And Data Systems) microcalciﬁcations and to allow a better surgical planning. Materials
and Method. 62 female Patients (age 50 ± 12) with screening detected 3–5 BI-RAD microcalciﬁcations underwent dynamic 3 T
contrast-enhanced breast MRI. After 30-day (range 24–36 days) period, 55 Patients underwent biopsy using stereotactic vacuum-
assistedbiopsy (VAB),5 Patients underwent stereotactic mammographically guided biopsy, and 2 Patients underwent MRI-guided
VAB. Results. Microhistology examination demonstrated 36 malignant lesions and 26 benign lesions. The analysis of MRI ﬁndings
identiﬁed 8 cases of MRI BI-RADS 5, 23 cases of MRI BI-RADS 4, 11 cases of MRI BI-RADS 3, 4 cases type A and 7 cases type B,
and 20 cases of MRI BI-RADS 1-2. MRI sensitivity, speciﬁcity, positive predictive value, and negative predictive value were 88.8%,
76.9%, 84.2%, and 83.3%, respectively.
1.Introduction
Mammographically detected microcalciﬁcations are early
diagnosed breast cancers, found in approximately 70% of
ductal carcinoma in situ (DCIS) [1, 2]. During the last 20
years, the prevalence of DCIS has grown from less than
5%, before the start of mammographic screening, to 15%–
30% in women regularly checked with mammography [3].
The extension of screening mammography has resulted in
a decreased number of patients who die of breast cancer,
because mammography is sensitive for the detection of
clinically occult breast cancer [4, 5]. Mammography has
high sensitivity and low speciﬁcity, the positive predictive
value (PPV) being 15%–30% for malignant nonpalpable
lesions[3].Thesensitivityofcontrast-enhancedMRimaging
in detecting invasive breast cancers has been extensively
shown to be very high (94–100%), with a speciﬁcity of
approximately 65–80% [6]. Conversely, until now, there is
no agreement regarding the sensitivity and speciﬁcity of
breast MRI for the detection of in situ ductal cancers,
and the role of MRI in characterizing breast microcalciﬁ-
cations remains a debated issue [7]. In fact the reported
values of sensitivity range between 45% and 100% and
the speciﬁcity between 37% and 95% [8]. A recent study
suggested that nonpalpable lesions with microcalciﬁcations
categorized as BI-RADS 3 should undergo a biopsy pro-
cedure until a more reliable system for the description
and classiﬁcation of microcalciﬁcations is available [9].
V A Bh a sas u ﬃcient sensitivity and speciﬁcity to replace
surgical biopsy and oﬀers valuable advantages for the eval-
uation of small concerning lesions and microcalciﬁcations
[10].
Thepurposeofourstudywastodeterminethefrequency
of malignancy in BI-RADS 3–5 microcalciﬁcations using
dynamic contrast-enhanced MR imaging ﬁndings in screen-
ing detected microcalciﬁcation lesions and its correlation
with histopathological ﬁndings.2 ISRN Oncology
2.MaterialsandMethod
2.1. Study Population. From January 2007 to December
2009 62 women with BI-RADS 3–5 microcalciﬁcations on
mammography underwent breast MRI before a stereotactic
biopsy using vacuum-assisted biopsy (VAB). In 8/62 patients
the microcalciﬁcations were associated with an opacity, and
in 1/62 patients the microcalciﬁcations were associated with
glandular distortion. The study received ethics committee
approval, and all patients provided informed consent after
a clear explanation of the beneﬁts and potential risks.
2.2. Mammography. Digital mammographic examinations
were performed with GE Senographe DS (General Electric,
Milwaukee, USA); mammographic magniﬁcation was per-
formed using the view that allowed the best visualisation of
the microcalciﬁcations, and the microcalciﬁcation extension
was evaluated using the standard views.
2.3. Mammography Interpretations. The digital mammo-
grams acquired were analyzed in a blinded fashion by two
expert radiologists. All cases of microcalciﬁcations were
classiﬁed according to the method proposed by American
College of Radiology [11], and only those classiﬁed as BI-
RADS 3–5 were selected.
2.4. MRI. MR imaging was performed in all cases before
microhistology. Dynamic MRI was performed during the
7–14th day of the menstrual period in fertile woman. The
instrument was a 3.0T (Achieva, Philips Healthcare, Best,
The Netherlands) MRI apparatus, equipped with 4 channels
reception dedicated coil. All the subjects underwent MRI
exam with SENSE technology. Patients were examined in
prone position with both breasts positioned inside the
coil. MRI images were acquired on axial planes. After a
survey acquisition, MRI protocol consisted of the following
sequences: T1 (TSE) (TR/TE 6.8/3.3ms; thickness, 3mm,
gap 0; matrix, 512 × 512), T2-TSE (TR/TE 3800/140ms;
thickness, 3mm, gap 0; matrix, 225×512), a short tau inver-
sion recovery sequence (STIR) (TR/TE/TI/4,000/42/155ms;
3.0mm, gap 0; 320 ×224), and a T1 dynamic sequence (2D)
(FFE) (TR/TE 290/4.6ms; ﬂip angle, 90◦; matrix 256 × 512;
thickness, 3mm; 8 dynamics; with 50s time resolution for
each). The T1 dynamic sequences were acquired by previous
0.1mmol/Kg gadolinium bolus injection (gadopentetic acid
and dimeglumine salt, Magnevist; Schering, Berlin, Ger-
many)administeredwitha2mL/secﬂux,followedbyasaline
ﬂush of 20mL.
2.5. MR Images Analysis. Any contrast enhancement in
the area of intermediate microcalciﬁcation was considered
positive (true positive). The absence of contrast enhance-
ment in the area of intermediate microcalciﬁcation was
considered negative. All exams were analysed by two radi-
ologists experienced in interpreting breast MRI. During the
assessment of MRI exams, the images of the mammography
previously performed were available. Each observer assessed
theenhancementcharacteristics,like:shape,nodular(assess-
ment of shape: circular, oval, lobulated, or irregular; edges
assessment: smooth, irregular, spiculated) or nonnodular
(distribution pattern assessment: nodular, linear/segmental,
dendritic). As to the evaluation of the signal/time intensity
ratio(Is/t), regions of interests (ROI) included in the suspect
lesions were manually outlined inside the major enhance-
ment areas. The Is/t curves were characterized depending
on the presence of persistent enhancement: type (1) with
a continuous increase in signal intensity on each successive
contrast-enhanced image; type (2) “plateau pattern” in
which an initial increase in signal intensity was followed
by a ﬂattening and ﬂuctuation of the enhancement curve;
type (3) “washout pattern,” with an initial increase and
subsequent decrease in signal intensity. Results of the MRI
study were classiﬁed into ﬁve BIRADS categories: MRI 1-2
negative/benign, MRI 3a probably benign lesion, and MRI
3bborderlinelesion/probablymalignant;BIRADS4-5:prob-
ably malignant/malignant [11]. The so-called borderline
breast lesions may lie on a spectrum of pathological entities
which are diﬃcult to distinguish from malignant lesions
[2, 3]. The borderline lesions recognised in this study are
atypical ductal hyperplasia, ﬂat atypia adenosis, and ductal
papilloma. Actually a MRI demonstrated that borderline
lesion is referred for a diagnostic surgical biopsy to exclude
the presence of a nearly carcinoma lesion.
2.6. VAB System. VAB VACORA (BARD) system was
adopted to carry out most parts of our biopsies. The system
is equipped with a MRI compatible, disposable coaxial
stainless steel introducer needed to guide the a-magnetic
ﬁne needle up to the area of interest. The needle consists of
two stainless steel cannula with 10Gauge outer diameter; the
inner cannula includes a window for the sample collection,
connected with the aspiration cylinder. The VACORA BARD
system can be employed as handheld device as well; it allows
pressure vacuum generation through an electric engine
equipped with a microprocessor. One radiologist with 6 year
of prior experience in VAB performed the biopsy with the
patients prone on a digital stereotactic table. Complete or
partial removal of the microcalciﬁcations was assessed in
all cases on two-view full-ﬁeld mammograms immediately.
If microcalciﬁcations had been removed completely or
almost completely, clips were placed through the 10-gauge
probe to identify the VAB site for sequent surgical excision
[12, 13]. The histopathological result was correlated with
the mammographic ﬁndings by both the radiologist and
pathologist in all cases.
2.7. Histological Diagnosis. The histological ﬁndings were
classiﬁed into two groups, malignant and benign. Malignant
lesions included inﬁltrative ductal cancer, ductal in situ
cancer (DCIS), and high-risk lesions as atypical ductal
hyperplasia, ﬂat atypia, and ductal papilloma. Lesions not
classiﬁed as malignant and high-risk lesions were identiﬁed
as benign lesions.ISRN Oncology 3
Table 1: Mx BI-RADS and histological correlation.
MX BI-RADS (N lesions) Histology, benign lesions Histology, malignant lesions
3 (23)
8 apocrine metaplasia 1 DCIS
6 typical ductal hyperplasia 1 ﬂat atypia
2 sclerosing adenosis 3 atypical ductal hyperplasia
2 ductal papilloma
4 (32)
5 apocrine metaplasia 20 DCIS
4 typical ductal hyperplasia 1 inﬁltrative ductal cancer
1 sclerosing adenosis 1 ductal papilloma
5( 7 ) 1D C I S
6 inﬁltrative ductal cancer
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Figure 1: (a-b) A case of MX BI-RADS 4; mammography shows a cluster of microcalciﬁcations in deep upper-outer quadrants of the left
breast. (c) MRI shows an irregular area with irregular and segmented contrast-enhancement with longitudinal development (about 15mm)
in deep retroareolar region, next to the cluster of microcalciﬁcation seen by Mammography; this case has been classiﬁed as MRI BI-RADS
4. (d) time-intensity curve documents heavy but not fast washin and slower washout of contrast-enhancement. Histology demonstrated a
DCIS.
3. Results
Microhistology examination demonstrated 36 malignant
lesions and 26 benign lesions. In particular of 36 malignant
lesions, 7 were described as inﬁltrative ductal cancer, 22 as
ductal in situ cancer (DCIS), 3 as atypical ductal hyperplasia,
1 as ﬂat atypia, and 3 as ductal papilloma; on the other hand
the 26 benignant lesions were represented by 13 apocrine
metaplasia, 10 typical ductal hyperplasia and, 3 sclerosing
adenosis. The mammographic examination of 62 Patients
showed 26 cases of BI-RADS 3, 29 cases of BI-RADS 4, and
7 cases of BI-RADS 5. In 8 patients the microcalciﬁcations
were associated with an opacity while in 1 patient the
microcalciﬁcations were associated with glandular distor-
tion. The correlation between mammography and histology
results demonstrated that of 23 cases of BI-RADS 3, 8 were4 ISRN Oncology
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Figure 2: (a-b) A case of MX BI-RADS 3; mammography shows a cluster of microcalciﬁcations in upper quadrants of left breast. (c) MRI
shows a millimetric pseudonodular contrast-enhancement without sure substratum in morphologic sequences in the same region of Mx
microcalciﬁcations; it has been classiﬁed as MRI BI-RADS 4. (d) The time-intensity curve has heavy but not fast washin and subsequent
plateau of contrast-enhancement. Histology conversely demonstrated a sclerosing adenosis.
apocrine metaplasia, 6 were typical ductal hyperplasia, 2
were sclerosing adenosis, 1 were DCIS, 1 was ﬂat atypia, 3
atypical ductal hyperplasia, and 2 ductal papilloma. Of 32
cases of BI-RADS 4, 5 were apocrine metaplasia, 4 typical
ductal hyperplasia, 1 was sclerosing adenosis, 20 DCIS, 1
inﬁltrativeductalcancer,and1ductalpapilloma;of7casesof
BI-RADS 5, 1 was DCIS and 6 were inﬁltrative ductal cancer
(Table 1). Mammographic sensitivity, speciﬁcity, positive
predictive value, and negative predictive value were 80.5%,
61.5%, 74.3%, and 69.5%, respectively. Including only the
DCIS ﬁndings, we found that mammographic sensitivity,
speciﬁcity, positive predictive value, and negative predictive
value were 95.4%, 61.5%, 67.7%, and 94.1%, respectively.
The analysis of MRI ﬁndings identiﬁed 8 cases of MRI
BI-RADS 5, 23 cases of MRI BI-RADS 4, 11 cases of MRI
BI-RADS 3, 4 cases type A and 7 cases type B, and 20 cases
of MRI BI-RADS 1-2. The correlation between MRI and
histology results showed that of 8 MRI BI-RADS 5, 7 cases
were conﬁrmed as inﬁltrative ductal cancer and 1 as DCIS; of
23 MRI BI-RADS 4, 17 were conﬁrmed by histology as DCIS
(Figure 1), whereas 1 were described as apocrine metaplasia,
3 as typical ductal hyperplasia, and 2 as sclerosing adenosis
(Figure 2); of MRI BI-RADS 3 type A, 1 was conﬁrmed as
apocrine metaplasia, 1 as typical ductal hyperplasia, and 1 as
sclerosingadenosis and1ductalpapilloma;ofMRIBI-RADS
3typeB,2wereconﬁrmedasatypicalductalhyperplasiaad1
asﬂatatypia,2asDCIS,and2ductalpapilloma;furthermore
of 20 cases of MRI BI-RADS 1-2, 17 were conﬁrmed by
histology as 11 apocrine metaplasia and 6 as typical ductal
hyperplasia, while 2 were revealed to be DCIS (Figure 3)
and 1 to be an atypical ductal hyperplasia (Table 2). MRI
sensitivity, speciﬁcity, positive predictive value, and negative
predictive value were 88.8%, 76.9%, 84.2%, and 83.3%,
respectively. Including only the DCIS ﬁndings, we found that
the MRI sensitivity, speciﬁcity, positive predictive value, and
negative predictive value were 90.9%, 76.9%, 76.9%, and
90.9%, respectively.
Of 62 patients, 18 (29%) did not show any kind of
contrast enhancement at MRI, while 44 (71%) showed
contrast enhancement; in particular 7 presented a dendritic
enhancement, 18 a linear or segmental enhancement, and 19
a nodular enhancement (Table 3).ISRN Oncology 5
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Figure 3: (a-b) A case of MX BI-RADS 4; mammography shows a
cluster of microcalciﬁcations in upper-outer quadrants of the right
breast.(c)ThiscasehasbeenclassiﬁedasMRIBI-RADS1-2because
there was not contrast-enhancement in upper-outer quadrants of
the right breast. Histology demonstrated a DCIS.
On Table 4 we analysed the time intensity curve corre-
lated with the MRI BI-RAD and we showed that of patients
with contrast enhancement, 6/44 had a type 1, 16/44 a type
2, and 22/44 a type 3.
Comparing MX and MRI results we found that 2 cases
of MX BI-RADS 4, identiﬁed subsequently as DCIS, were
described as MRI BI-RADS 1-2, because they did not show
contrast enhancement (Figure 3).
Despite that, with regard to disease extension, we found
that mammography underestimation existed in 6/29 cases
(20.9%), conﬁrmed later by histology; in particular of
7 inﬁltrative ductal cancer histologically detected, MRI
permitted to visualise 2 cases of multifocality and 1 case of
multicentricity, whereas of 22 DCIS, MRI visualised 2 cases
of multifocality and 1 case of multicentricity.
4. Discussion
Mammography is extremely sensitive in detecting microcal-
ciﬁcations even though it does not permit to distinguish
malignant from benign lesions and invasive carcinoma
from DCIS [14]. In fact in our population sensitivity of
mammography in detection of cancer and early cancer
related to microcalciﬁcations was 80.5%, and speciﬁcity
was only 61.5%. The presence of microcalciﬁcations on
mammography is often referred to early diagnosed breast
cancersandisfoundinapproximately70%ofminimalbreast
cancers and frequently in DCIS [15]. Stomper and Margolin
reports that mammographically detected microcalciﬁcations
are the only sign in 72% of clinically occult DCIS lesions
[15]. The low speciﬁcity of microcalciﬁcations as a feature of
malignancy, 10–70% according to literature, is histologically
demonstrated in a high number of diagnostic biopsies [14].
On the other hand, approximately 75% of lesions that are
detected, suspected, or indeterminate on mammography are
revealed to be benign at biopsy [16], suggesting that many
biopsies are performed unnecessarily because the indication
for VAB has not yet been fully established.
Dynamic contrast-enhanced MRI is an eﬀective diagnos-
tic technique for symptomatic breast diseases. However its
role in evaluating clinically occult disease associated with
mammographically detected suspicious microcalciﬁcations
has to be clariﬁed. Mammography or ultrasound cannot be
replaced by breast MRI even when it is indicated to perform
biopsy. Nevertheless contrast-enhanced dynamic breast MRI
is actually the best technique in the detection of multifocality
or bilateral incidence of carcinoma mainly in dense type of
breast. In our study mammography underestimated disease
extension in 6 cases (20.9%), in particular of 7 inﬁltrative
ductal cancer histologically detected, MRI permitted to
visualise2casesofmultifocalityand1caseofmulticentricity,
whereas of 22 DCIS, MRI visualised 2 cases of multifocality
and 1 case of multicentricity. Knowing that allowed a better
surgical planning in these patients. Previous MR studies
have reported variable accuracy of MRI for classiﬁcation
of microcalciﬁcations [17, 18]. Early studies suggested that
dynamic contrast-enhanced MRI should not be used to
assess microcalciﬁcations [19, 20]b e c a u s eM R Ii su n a b l et o
identify small calciﬁcations, which are typically associated
with malignant disease. Westerhof et al. [19]r e p o r t e da
sensitivity of 45% and a speciﬁcity of 72% for dynamic
MRI in patients with mammographically suspicious micro-
calciﬁcations. In another study, Gilles et al. [20]o b s e r v e da
sensitivity of 95% and a speciﬁcity of only 51% for MRI;
in this case, speciﬁcity was potentially lower because the
presence or absence of contrast uptake in the breast was the
only parameter used to deﬁne the malignancy. The latest
studies have a better rate of diagnosis due to technological
improvements. Bazzocchi et al. [17] reported that MRI using
up-to-date 3D sequences and combined morphological-
kinetic evaluation had a sensitivity of 87%, a speciﬁcity
of 68%, and an accuracy of 80%. The high variability of
MRI diagnostic accuracy in evaluating microcalciﬁcations
reported in these studies is related to the use of diﬀerent
criteria as lesion size, histological variability of cancer, cancer
angiogenesis, type of enhancement, enhancement pattern,
distribution in the breast, margins (regular, irregular), and
use of diﬀerent pulse sequences and scan planes [20]. Cilotti
et al. in an analysis of morphological and dynamic features
of BIRADS 3–5 microcalciﬁcations observed a sensitivity of6 ISRN Oncology
Table 2: MRI BI-RADS and histological correlation.
MRI BI-RADS (N lesions) Histology, benign lesions Histology, malignant lesions
1-2 (20) 11 apocrine metaplasia 2 DCIS
6 typical ductal hyperplasia 1 atypical ductal hyperplasia
3A (4)
1 apocrine metaplasia
1 ductal papilloma 1 typical ductal hyperplasia
1 sclerosing adenosis
3B (7)
2 atypical ductal hyperplasia
1 ﬂat atypia
2D C I S
2 ductal papilloma
4 (23)
1 apocrine metaplasia
17 DCIS 3 typical ductal hyperplasia
2 sclerosing adenosis
5( 8 ) 7 inﬁltrative ductal cancer
1D C I S
Table 3: MRI enhancement.
MRI BI-RADS Enhancement No enhancement
Dendritc Linear/segmental Nodular
1-2 21 8
3A 4
3B 34
4 14 9
57 1
Table 4: MRI time-intensity curve of enhancement.
MRI BI-RADS Time intensity curve No enhancement
Type 1 Type 2 Type 3
1-2 2 18
3A 4
3B 61
4 10 13
5 8
MRI of 73%. They considered MRI BIRADS categories 1,
2, and 3 as benign, according to histopathological diagnosis
and 4 and 5 as malignant [21]. In our study, the sensitivity
of contrast-enhanced MRI was higher (88.8% versus 73% in
Cilotti’s study). Compared with previous studies, our study
couldshowbetterresults,inadditiontotheuseofup-to-date
3D sequences, probably because of the revised MRI classiﬁ-
cation system. In fact we proposed a more detailed deﬁnition
of BIRADS 3 enhancement to detect border-line lesions
such as atypical ductal hyperplasia, ﬂat atypia, and ductal
papilloma. In our study we observed that in MRI BI-RADS
3 the angiogenesis gave in 8 cases a nodular enhancement
and in 3 cases a linear/segmental enhancement. Furthermore
we noticed that in 4 cases the time-intensity curve was type
1, in 6 cases was type 2 while in one case was type 3. So
correlating the type of enhancement and its time-intensity
curve with histological ﬁndings, we classiﬁed MRI BI-RADS
3 in two subgroups (MRI BI-RADS 3A and MRI BI-RADS
3B). In fact, in 3 cases of MRI BI-RADS 3A the histology
revealed 3 benign lesions, and in 5 cases of MRI BI-RADS
3B histology revealed border-line lesions (2 atypical ductal
hyperplasia, 1 ﬂat atypia, and 2 ductal papilloma). The so-
calledborder-linebreastlesionsarelesionswhicharediﬃcult
to distinguish from malignant lesions [22–24]. They are
represented by ductal papilloma, atypical ductal hyperplasia,
and ﬂat atypia. As deﬁned by the World Health Organization
(WHO) Working Group on Pathology and Genetics of
Tumors of the Breast [25], epithelial atypia is divided into
atypical ductal hyperplasia, ﬂat epithelial atypia (or DIN
1a). Due to a lack of standardized terminology, atypical
ductal hyperplasia and ﬂat atypia are sometimes poorly
diﬀerentiated on pathological examination [26]. As deﬁned
by the WHO [23, 24] ,F E Ai sa n“ i n t r a d u c t a la l t e r a t i o n
characterized by replacement of the native epithelial cells
by a single or 3–5 layers of mildly atypical cells”. However
the guide-lines consider to treat the borderline lesions as anISRN Oncology 7
early breast cancer and recommend surgical excision. Paying
attention to these kind of borderline lesions permits to avoid
the transformation of a small lesion into an invasive cancer.
In conclusion breast MRI could change the prognosis of
the breast cancer detecting the border-line lesions that are
recently deﬁned, to be more precise, the precursors of the
early breast cancer.
5. Conclusions
In conclusion, our study has revealed that contrast-enhanced
breast MRI have a better sensitivity and speciﬁcity in the
evaluation of the early breast cancer related to mammo-
graphically detected microcalciﬁcations, than other studies.
In fact in our experience breast MRI sensitively improved the
percentageofdiagnosisofmalignancyinmammographically
detected microcalciﬁcation. This is due to the use of diﬀerent
criteria as lesion size, histological variability of cancer, cancer
angiogenesis, type and pattern of enhancement, margins,
and use of 3D sequences but specially to a revision of MRI
BI-RADS classiﬁcation, considering the border-line lesions
as proposed by the World Health Organization (WHO)
Working Group on Pathology and Genetics of Tumors of the
Breast.
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